Literature DB >> 20349662

Are papillary microcarcinomas of the thyroid gland revealed by cervical adenopathy more aggressive?

Bassam Abboud1, Ronald Daher, Ghassan Sleilaty, Gerard Abadjian, Claude Ghorra.   

Abstract

Therapeutic attitudes for papillary thyroid microcarcinoma (PTMC) range from observation alone to aggressive management. Clinicopathologic features, therapeutic options, and follow-up results are described in a series of PTMC revealed by cervical adenopathies. Twelve patients were enrolled in this retrospective study. They were all treated by total/near-total thyroidectomy with dissection of suspect cervical lymph nodes followed by radioactive iodine (RAI) and suppressive L-thyroxine therapies. Mean age at diagnosis was 32 years with a mean elapsed time to diagnosis of 45.3 months. Fine needle aspiration cytology and excisional biopsy of the lymph node led to a diagnosis in all cases. Cervical mass was ipsilateral to primary tumor in six patients (50%). Multifocality, bilaterality, and capsular invasion were encountered in 66.7, 66.7, and 41.7 per cent of patients, respectively. Lymph node involvement was bilateral in seven patients (58.3%) of whom thyroid foci were unilateral in two. No complications of thyroidectomy were encountered. At 60-month-follow up, no recurrence or metastasis was noted. PTMC revealed by cervical lymph node metastasis shows aggressive clinicopathologic features. They must be considered as papillary thyroid cancers and managed by total/near-total thyroidectomy with bilateral lymph node exploration followed by RAI therapy and suppressive L-thyroxine doses.

Entities:  

Mesh:

Year:  2010        PMID: 20349662

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  4 in total

1.  Clinical and pathologic predictors of central lymph node metastasis in papillary thyroid microcarcinoma: a retrospective cohort study.

Authors:  C Y Gui; S L Qiu; Z H Peng; M Wang
Journal:  J Endocrinol Invest       Date:  2017-09-07       Impact factor: 4.256

2.  Risk factors for predicting central lymph node metastasis in papillary thyroid microcarcinoma.

Authors:  Dequan Xu; Xiaoying Lv; Song Wang; Wenjie Dai
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

3.  Analysis of risk factors for cervical lymph node metastasis of papillary thyroid microcarcinoma: a study of 268 patients.

Authors:  Jian-Hua Gu; Yan-Na Zhao; Rong-Li Xie; Wen-Juan Xu; Da-Li You; Zhi-Feng Zhao; Fei Wang; Jian Fei
Journal:  BMC Endocr Disord       Date:  2019-11-15       Impact factor: 2.763

4.  Treatment for papillary thyroid microcarcinoma.

Authors:  Lan Shi; Jun-Hua Chen; Shun-Tao Wang; Yi-Quan Xiong; Tao Huang
Journal:  Contemp Oncol (Pozn)       Date:  2013-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.